87E Stock Overview
A clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Dianthus Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$19.20 |
| 52 Week High | US$29.60 |
| 52 Week Low | US$10.50 |
| Beta | 0 |
| 11 Month Change | -25.58% |
| 3 Month Change | -27.27% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 64.10% |
Recent News & Updates
Recent updates
Shareholder Returns
| 87E | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -12.7% | -0.7% | 0.2% |
| 1Y | n/a | -17.2% | 8.5% |
Return vs Industry: Insufficient data to determine how 87E performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 87E performed against the German Market.
Price Volatility
| 87E volatility | |
|---|---|
| 87E Average Weekly Movement | 7.6% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 87E's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 87E's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 53 | Marino Garcia | dianthustx.com |
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Dianthus Therapeutics, Inc. Fundamentals Summary
| 87E fundamental statistics | |
|---|---|
| Market cap | €634.95m |
| Earnings (TTM) | -€64.43m |
| Revenue (TTM) | €5.15m |
123.2x
P/S Ratio-9.9x
P/E RatioIs 87E overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 87E income statement (TTM) | |
|---|---|
| Revenue | US$5.37m |
| Cost of Revenue | US$0 |
| Gross Profit | US$5.37m |
| Other Expenses | US$72.46m |
| Earnings | -US$67.09m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.27 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,250.32% |
| Debt/Equity Ratio | 0% |
How did 87E perform over the long term?
See historical performance and comparison